Clinical Trials
35
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Efficacy and Safety of a Rilpivarine-based Antiretroviral Tratment Regimen in HIV- Infected Patients With Liver Metabolic Disease Who Maintain Udetectable HIV Viral Load
- Conditions
- Fatty Liver DiseaseHIV Infections
- Interventions
- Drug: Continue with their previous treatment. Any previous HAART that does not contain Rilpivirine.
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 63
- Registration Number
- NCT05898841
- Locations
- 🇪🇸
Hospital Universitario Gregorio Marañon, Madrid, Spain
🇪🇸Hospital universitario Infanta Leonor, Madrid, Spain
🇪🇸Hospital Universitario Infanta Sofía, Madrid, Spain
Phase IV, a Clinical Trial to Assess Safety and Convenience of the Change From DTG/3TC to BIC/FTC/TAF in People With HIV, Good Virological Control and Neuropsychiatric Vulnerabilities
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 84
- Registration Number
- NCT05549180
- Locations
- 🇪🇸
H. Universitario Son Espases, Palma De Mallorca, Islas Baleares, Spain
🇪🇸Hospital de Bellvitge, Barcelona, Spain
🇪🇸CHUAC, Coruña, Spain
Simplified Model of Linkage and Retention to Care, Using a Mobile Unit and a Same-day Test and Treat Approach Among Excluded Population. (SIMPLIFIED)
- Conditions
- HIV Infections
- Interventions
- Drug: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 100
- Registration Number
- NCT05405751
- Locations
- 🇪🇸
H. Infanta Leonor, Madrid, Spain
DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV:
- Conditions
- HIV-1-infection
- Interventions
- Drug: Dolutegravir/Lamivudine as a single pillDrug: Bictegravir/Emtricitabine/Tenofovir alfenamide as a single pill.
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 554
- Registration Number
- NCT04884139
- Locations
- 🇪🇸
H. Marina Baixa, Villajoyosa, Alicante, Spain
🇪🇸H. General Universitario Dr. Balmis, Alicante, Spain
🇪🇸H. Germans Trias i Pujol, Barcelona, Spain
Lamivudine/Dolutegravir in Virologically Suppressed Subjects With Expected or Confirmed Resistance to Lamivudine
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 121
- Registration Number
- NCT04880785
- Locations
- 🇪🇸
H. Álvaro Cunqueiro, Vigo, Pontevedra, Spain
🇪🇸H. de Elche, Alicante, Spain
🇪🇸H. General de Alicante, Alicante, Spain
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next